Sponsored by Pfizer - For actress and producer Elizabeth Banks, turning 50 meant prioritizing preventative care to stay ...
Vaxcyte's VAX-24 Phase 2 trial showed a safety profile similar to PCV20, with strong immune responses and no serious ...
Clinical Trials Arena on MSN1d
Vaxcyte stock sinks despite Phase II IPD vaccine trial successVaxcyte’s stock has dropped around 45% despite a Phase II trial of its invasive pneumococcal disease (IPD) vaccine meeting ...
Vaxcyte plunges 56% even though its VAX-24 pneumonia vaccine shows positive phase two results in infants. Read more here.
Vaxcyte (PCVX) shared topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, ...
MSD has received approval from the European Commission (EC) for Capvaxive, a pneumococcal 21-valent conjugate vaccine, to prevent invasive disease and pneumonia due to Streptococcus pneumoniae ...
Merck MRK announced that the European Commission (“EC”) has approved its 21-valent pneumococcal conjugate vaccine (“PCV”), Capvaxive, for the prevention of invasive pneumococcal disease ...
Two words come to mind for Elizabeth Banks after her showdown with shingles: "Not fun." ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback